CYP19A1 and breast carcinoma: In fact, a decline in the mortality rate of the majority of ER+ breast cancer cases in recent years have been due to the success of endocrine therapies with aromatase inhibitors such as letrozole, anastrozole, and exemestane and anti-estrogens such as tamoxifen.